Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-HL-15-022

Stem Cell-Derived Blood Products for Therapeutic Use (R01)

Closed on February 20, 2015.

Posted
November 7, 2014
Close date
February 20, 2015
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
7
7 new
Median first-year cost
$460,500
$3,365,039 in all
Institutions
7
7 contact PIs
Patents
1
from 1 funded project

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. BOSTON CHILDREN'S HOSPITAL1
  2. CHILDREN'S HOSP OF PHILADELPHIA1
  3. JOHNS HOPKINS UNIVERSITY1
  4. UNIVERSITY OF ILLINOIS AT CHICAGO1
  5. UNIVERSITY OF ROCHESTER1

and 2 other institutions

Most frequent study sections

  1. Special Emphasis Panel (ZHL1 CSR-B (S1))7
7 awards under RFA-HL-15-022 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2015Megakaryocyte Transcription Factor Activation to Enhance In Vitro Platelet Production from Human IPSCs1R01HL130793-01Cantor, Alan B.BOSTON CHILDREN'S HOSPITAL, MAFirst-year cost $565,075Study section ZHL1
FY2015Genetically enhanced human erythrocytes generated from expandable stem cells1R01HL130676-01Cheng, LinzhaoJOHNS HOPKINS UNIVERSITY, MDFirst-year cost $508,325Study section ZHL1
FY2015Optimization of Ex Vivo- and In Vivo- Generated Platelets1R01HL130698-01French, Deborah LynnGadue, Paul JPoncz, MortimerCHILDREN'S HOSP OF PHILADELPHIA, PAFirst-year cost $506,000Study section ZHL1
FY2015Erythroid precursor self-renewal1R01HL130670-01Palis, JamesUNIVERSITY OF ROCHESTER, NYFirst-year cost $460,500Study section ZHL1
FY2015Controlling an Ontogenic Masterswitch to Maximize Thrombopoiesis1R01HL130550-01Goldfarb, Adam N.UNIVERSITY OF VIRGINIA, VAFirst-year cost $460,426Study section ZHL1
FY2015Generating Human Cord-Blood-Derived Functional Megakaryocytes and platelets.1R01HL130760-01Mahmud, NadimMiller, William MUNIVERSITY OF ILLINOIS AT CHICAGO, ILFirst-year cost $452,300Study section ZHL1
FY2015Universal Donor Megakaryocytes1R01HL130770-01Russell, David WUNIVERSITY OF WASHINGTON, WAFirst-year cost $412,413Study section ZHL1
Newest fiscal year first, then first-year cost.

Patents from its funded projects

1 patent names 1 of the 7 funded projects.

  1. US 10,260,043 (opens the patent at USPTO, a PDF, in a new tab)Human Extensively Self-Renewing Erythroblasts (ESRE)Granted April 16, 2019 to University of RochesterR01HL130670 · UNIVERSITY OF ROCHESTER, NY

Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.

Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-17-0.3.6. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.